SCHEMBL19610364

SCHEMBL19610364

Cn1c(C=C(N)C(=O)ON)cc2sccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.42
KDM1A O60341 5/20 0.40
RCOR1 Q9UKL0 5/20 0.40
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
RAB9A P51151 5/20 0.40
NPC1 O15118 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 7/20 0.39
ALDH1A1 P00352 5/20 0.39
TP53 P04637 3/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19610432 0.85 KDM1A (0.44) KDM1ARCOR1MAPTSMN1; SMN2RAB9A
SCHEMBL19636588 0.73 PIM1 (0.43) PIM1KDM1ARCOR1MAPTSMN1; SMN2
SCHEMBL1788259 0.72 PIM1 (0.52) PIM1KDM1ARCOR1MAPTSMN1; SMN2
SCHEMBL15870942 0.70 PIM1 (0.48) PIM1KDM1ARCOR1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL22406161 0.70 PIM1 (0.51) PIM1KDM1ARCOR1MAPTSMN1; SMN2
SCHEMBL18952163 0.69 KDM1A (0.60) KDM1ARCOR1MAPTSMN1; SMN2RAB9A
SCHEMBL3766716 0.64 KDM1A (0.64) KDM1ARCOR1MAPTSMN1; SMN2RAB9A
SCHEMBL21022849 0.64 MAPT (0.49) KDM1ARCOR1MAPTSMN1; SMN2RAB9A
SCHEMBL19610365 0.64 MAPT (0.49) KDM1ARCOR1MAPTSMN1; SMN2RAB9A
SCHEMBL22442065 0.64 KDM1A (0.56) KDM1ARCOR1MAPTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10961255-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2021-03-30 US disclosed
EP-3458460-B1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2020-12-09 EP disclosed
US-20200299303-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-09-24 US disclosed
US-10562914-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-02-18 US disclosed
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-05-23 US disclosed
EP-3458460-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2019-03-27 EP disclosed
WO-2017198780-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-11-23 WO disclosed
EP-3246330-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, DOT1L PIM1 686/4885KDM1A 2/4885RCOR1 74/4885
US-20200299303-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS DOT1L, KDM1B, KDM1A PIM1 677/4885KDM1A 3/4885RCOR1 77/4885
US-10562914-B2 Imidazoles as histone demethylase inhibitors KDM1B, KDM1A, DOT1L PIM1 686/4885KDM1A 2/4885RCOR1 74/4885
US-10961255-B2 Imidazoles as histone demethylase inhibitors DOT1L, KDM1B, KDM1A PIM1 677/4885KDM1A 3/4885RCOR1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.